Boston Life Sciences announces completion of patient enrollment in its Therafectin trial.BOSTON--(BUSINESS WIRE)--April 1, 1997--Boston Life Sciences Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BLSI BLSI Boston Life Sciences, Inc. ) announced that it had completed patient enrollment in its Phase III trial for Therafectin(R), the company's oral drug for the treatment of Rheumatoid Arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . The company said that all required patients had been enrolled into the double-blind, placebo-controlled trial and based on the 20 week duration of the study, that results are expected to be available in the second half of 1997. "We have been extremely pleased with the conduct of the study and the quality of the data that has been generated thus far," stated Marc E. Lanser, M.D., chief scientific officer of BLSI. "We are eagerly looking forward to the completion of the study later this year and to the analysis of the data. Although the outcome cannot be predicted in advance, if the results of the trial are statistically significant in favor of Therafectin, this will be the second solidly successful Phase III trial for Therafectin, which would provide additional important evidence of Therafectin's efficacy and safety for the treatment of Rheumatoid Arthritis," added Dr. Lanser. BLSI is developing novel treatments for cancer, autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . In addition to Therafectin, BLSI's products in clinical trials or in preclinical development include Troponin I troponin I n. A subunit of troponin found in muscle and cartilage that inhibits the formation of blood vessels and is under investigation as a potential cancer therapy. , a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. CONTACT: Boston Life Sciences, Inc. Marc E. Lanser, M.D./S. David Hillson 617/425-0200 or Martin E. Janis & Co. Beverly Jedynak 312/943-1100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion